Ebrahim Mohamed is a Synthetic Organic Chemist by training with over 15 years’ experience in pharmaceuticals with expertise covering business development, product development, technology transfers, process optimizations and cGMP.
After completing his PhD from the University of Cape Town in 2009, he joined the Science and Innovation (S&I) Department at the Biovac Institute (BIOVAC) where he established his expertise in the development of glycoconjugate vaccines. As Group Leader he currently manages all the CMC related activities with the Science and Innovation department. He has accumulated experience in both inward and outward bound technology transfers of clinical vaccine candidates and commercial products.
In 2015 Ebrahim became a key member of the secretariat team of the African Vaccine Manufacturing Initiative (AVMI) where he has played a pivotal part in assisting with the coordination of the AVMI Vaccine Manufacturing and Procurement in Africa (VMPA) study. Subsequently elected as a member of the AVMI board, Ebrahim represented the Southern African Region between 2016 and 2021. In 2021 he was also elected as part of the Scientific Working group addressing Technology and IP in the Partnerships for African Vaccine Manufacturing (PAVM) study, as well as being elected to serve on Emerging Biopharmaceuticals Manufacturers Network (EBPMN) scientific committee. Ebrahim has published several publications in reputable peer-reviewed journals.